[go: up one dir, main page]

UA97346C2 - Стабильная эмульсионная композиция - Google Patents

Стабильная эмульсионная композиция

Info

Publication number
UA97346C2
UA97346C2 UAA200713277A UAA200713277A UA97346C2 UA 97346 C2 UA97346 C2 UA 97346C2 UA A200713277 A UAA200713277 A UA A200713277A UA A200713277 A UAA200713277 A UA A200713277A UA 97346 C2 UA97346 C2 UA 97346C2
Authority
UA
Ukraine
Prior art keywords
emulsion composition
stable emulsion
stable
compound
adjusted
Prior art date
Application number
UAA200713277A
Other languages
English (en)
Ukrainian (uk)
Inventor
Наоки АСАКАВА
Такаюки Доэн
Original Assignee
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37308111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA97346(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед
Publication of UA97346C2 publication Critical patent/UA97346C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)

Abstract

Изобретение касается стабильной эмульсионной композиции, содержащей (А) соединение, стабильное в кислой среде, а именно этил (6R)-6-[N-(2-хлор-4-фторфенил)сульфамоил]циклогекс-1-ен-1-карбоксилат, (В) 1, 2 или более буферов (рН от приблизительно 3,7 до приблизительно 5,5), (С) анионный синтетический фосфолипид в качестве эмульгатора, и (D) компонент, который выбирают из группы, содержащей масло, эмульгатор, воду или их комбинацию; а также способа получения данной эмульсионной композиции.
UAA200713277A 2005-04-28 2006-04-27 Стабильная эмульсионная композиция UA97346C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005131807 2005-04-28
PCT/JP2006/309213 WO2006118329A1 (ja) 2005-04-28 2006-04-27 安定な乳化組成物

Publications (1)

Publication Number Publication Date
UA97346C2 true UA97346C2 (ru) 2012-02-10

Family

ID=37308111

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200713277A UA97346C2 (ru) 2005-04-28 2006-04-27 Стабильная эмульсионная композиция

Country Status (24)

Country Link
US (1) US20100016381A1 (ru)
EP (2) EP2255785A3 (ru)
JP (2) JP5236287B2 (ru)
KR (1) KR101321633B1 (ru)
CN (2) CN102670503A (ru)
AR (1) AR054264A1 (ru)
AU (1) AU2006241671B2 (ru)
BR (1) BRPI0610029A2 (ru)
CA (1) CA2605773C (ru)
CR (2) CR9495A (ru)
GE (1) GEP20105031B (ru)
IL (1) IL186673A (ru)
MA (1) MA29487B1 (ru)
ME (1) MEP10209A (ru)
MX (1) MX2007013407A (ru)
MY (1) MY147790A (ru)
NO (1) NO20075985L (ru)
NZ (1) NZ563225A (ru)
PE (1) PE20061437A1 (ru)
RU (1) RU2428204C2 (ru)
TW (1) TWI462745B (ru)
UA (1) UA97346C2 (ru)
WO (1) WO2006118329A1 (ru)
ZA (1) ZA200710193B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007132825A1 (ja) * 2006-05-15 2007-11-22 Takeda Pharmaceutical Company Limited 医薬
US20100062066A1 (en) * 2006-11-14 2010-03-11 Acusphere, Inc Formulations of Tetrahydropyridine Antiplatelet Agents for Parenteral or Oral Administration
US20080234376A1 (en) * 2007-03-21 2008-09-25 Taiwan Liposome Company (A Taiwan Corporation) Emulsion composition comprising prostaglandin e1
CN101229174B (zh) * 2008-01-25 2010-12-15 广东一品红药业有限公司 一种含有盐酸依匹斯汀的抗过敏组合物
US7829513B2 (en) * 2009-03-12 2010-11-09 Greenology Products, Inc. Organic cleaning composition
SG10201503402XA (en) 2010-01-27 2015-06-29 Takeda Pharmaceutical Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent
CN103458929A (zh) * 2011-03-31 2013-12-18 富士胶片株式会社 含有前列腺素的脂肪乳剂
JP5894752B2 (ja) * 2011-03-31 2016-03-30 富士フイルム株式会社 プロスタグランジン含有脂肪乳剤
JP2012214430A (ja) * 2011-03-31 2012-11-08 Fujifilm Corp プロスタグランジン含有脂肪乳剤
US9994514B2 (en) 2012-05-08 2018-06-12 Aeromics, Inc. Methods of treating cerebral edema and spinal cord edema
AU2014346682B2 (en) 2013-11-06 2020-03-12 Aeromics, Inc. Novel formulations
US20170246136A1 (en) * 2014-09-24 2017-08-31 OliVentures, Inc. Pharmaceutical product, medical food or dietary supplement for preventing cancer and inflammatory diseases
US12076397B2 (en) 2016-05-10 2024-09-03 The Regents Of The University Of Michigan Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration
WO2021252449A1 (en) * 2020-06-08 2021-12-16 Harm Reduction Therapeutics, Inc. Sterilized formulations

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380737A (en) * 1989-05-04 1995-01-10 Sterling Winthrop Inc. Saccharin derivative proteolytic enzyme inhibitors
US5236917A (en) * 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5128339A (en) * 1990-11-01 1992-07-07 Sterling Winthrop Inc. Proteolytic enzyme inhibition method
US5306818A (en) * 1990-11-01 1994-04-26 Sterling Winthrop Inc. Tetrahydro 2-saccharinylmerthyl aryl carboxylates
US5250696A (en) * 1990-11-01 1993-10-05 Sterling Winthrop Inc. 2-saccharinylmethyl aryl carboxylate
US5512589A (en) * 1990-11-01 1996-04-30 Sterling Winthrop Inc. 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
JP2836599B2 (ja) 1996-08-09 1998-12-14 日本電気株式会社 通信制御装置
ES2232114T3 (es) * 1998-03-09 2005-05-16 Takeda Pharmaceutical Company Limited Derivados de cicloalqueno, procedimiento para su produccion, y uso.
CH693846A5 (de) 1998-03-11 2004-03-15 Mitsubishi Electric Corp Gronlingelektrode zur Oberflachenbehandlung durch Funkenerosion.
PL353635A1 (en) * 1999-08-06 2003-12-01 Takeda Chemical Industries, Ltd.Takeda Chemical Industries, Ltd. Substituted aromatic-ring compounds, process for producing the same, and use
US6532316B1 (en) * 1999-11-10 2003-03-11 Avanex Corporation Bi-directional polarization-independent optical isolator
AU776851B2 (en) * 2000-02-04 2004-09-23 Takeda Pharmaceutical Company Limited Stable emulsion compositions
JP4863553B2 (ja) * 2000-02-04 2012-01-25 武田薬品工業株式会社 安定な乳化組成物
JP2003033195A (ja) * 2001-07-24 2003-02-04 Kyowa Hakko Kogyo Co Ltd テトラヒドロクルクミン類の製造方法
US7960416B2 (en) * 2001-08-03 2011-06-14 Takeda Pharmaceutical Company Limited Stable emulsion composition
US20030220284A1 (en) * 2002-02-22 2003-11-27 Patricia Yotnda Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
RU2335279C2 (ru) * 2002-12-06 2008-10-10 Оцука Фармасьютикал Фэктори, Инк. Жировые эмульсии, содержащие пропофол
JP4715515B2 (ja) * 2003-10-03 2011-07-06 小野薬品工業株式会社 （２ｒ）−２−プロピルオクタン酸を有効成分とする薬剤
EP2260869A3 (en) * 2006-04-20 2011-03-23 Takeda Pharmaceutical Company Limited Pharmaceutical product

Also Published As

Publication number Publication date
MEP10209A (en) 2011-12-20
RU2007144071A (ru) 2009-06-10
NO20075985L (no) 2008-01-25
ZA200710193B (en) 2009-07-29
KR20080011413A (ko) 2008-02-04
CN102670503A (zh) 2012-09-19
GEP20105031B (en) 2010-06-25
TWI462745B (zh) 2014-12-01
AU2006241671A1 (en) 2006-11-09
EP1875926A4 (en) 2013-01-16
CN101212986A (zh) 2008-07-02
US20100016381A1 (en) 2010-01-21
BRPI0610029A2 (pt) 2011-10-11
AU2006241671B2 (en) 2012-06-07
NZ563225A (en) 2011-01-28
EP2255785A3 (en) 2013-01-16
KR101321633B1 (ko) 2013-10-22
CA2605773C (en) 2014-04-08
IL186673A0 (en) 2008-01-20
CA2605773A1 (en) 2006-11-09
JPWO2006118329A1 (ja) 2008-12-18
MY147790A (en) 2013-01-31
CN101212986B (zh) 2015-01-14
JP2013040215A (ja) 2013-02-28
IL186673A (en) 2013-08-29
AR054264A1 (es) 2007-06-13
MA29487B1 (fr) 2008-05-02
MX2007013407A (es) 2008-01-15
CR9495A (es) 2008-02-22
CR20130666A (es) 2014-03-13
PE20061437A1 (es) 2007-01-25
JP5236287B2 (ja) 2013-07-17
EP1875926A1 (en) 2008-01-09
RU2428204C2 (ru) 2011-09-10
EP2255785A2 (en) 2010-12-01
TW200724159A (en) 2007-07-01
WO2006118329A1 (ja) 2006-11-09

Similar Documents

Publication Publication Date Title
UA97346C2 (ru) Стабильная эмульсионная композиция
MX2009006594A (es) Formulaciones de ph regulado y estables que contienen polipeptidos.
MX348936B (es) Formulaciones de antibioticos, dosis unitarias, equipos y metodos.
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
EP1482912A4 (en) Naltrexone hydrochloride COMPOSITIONS
MX346822B (es) Pro-drogas de compuestos de 2,4-pirimidindiamina y sus usos.
TW200714294A (en) Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
UA93351C2 (ru) Производные фталазина kak ингибиторы parp
CR8824A (es) Derivados de 2-carbamida-4-feniltiazol, su preparacion y su aplicacion en terapeutica
TW200738283A (en) Formulations of conjugated estrogens and bazedoxifene
RS50510B (sr) Formulacije koje sadrže ekteinascidin i disaharid
MX2007001035A (es) Metodo para producir una composicion, la composicion y su uso.
EP1704853A3 (en) Water-in-silicone emulsion compositions
MX341064B (es) Variantes de la familia il-1.
BRPI0603197A (pt) composição de toner
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
GB0414594D0 (en) Aqueous composition 1
WO2007022321A3 (en) Substituted indoles and use thereof
SG131082A1 (en) Fabp4 as marker for a toxic effect
TW200517117A (en) Stabilized compositions containing an oxygen-labile active agent
CO5580729A2 (es) Composiciones nutricionales que comprenden cistationina
MY162185A (en) Alumina particles and methods of making the same
PL1922128T3 (pl) Element do zmniejszania zawartości drobnego pyłu w powietrzu, za pomocą mchów i/lub porostów
PL1677818T3 (pl) Stabilne kompozycje wodne zawierające G-CSF
MX2007010099A (es) Las 1,3-tiazol-5-carboxamidas utiles como agentes quimioterapeuticos contra el cancer.